Pharmaceutical Product Monograph: Atazanavir Capsules (150 mg / 200 mg / 300 mg)
In the pharmaceutical industry, Atazanavir is a potent, second-generation Azapeptide Protease Inhibitor (PI). As a pharmacist and manufacturer, I view this molecule as a “Precision Viral Blocker”—it is technically designed to inhibit the HIV-1 protease enzyme, preventing the processing of viral gag-pol polyproteins and resulting in the production of immature, non-infectious virions.
At your WHO-GMP facility in Mumbai, Atazanavir is a high-value Antiretroviral (ARV) SKU. It is a cornerstone of “highly active antiretroviral therapy” (HAART) for both treatment-naive and treatment-experienced patients.
Therapeutic Profile: Primary Indications
Atazanavir is indicated for the treatment of HIV-1 infection in adults and pediatric patients (6 years and older, weighing at least 15 kg).
| Clinical Context | Technical Rationale |
| First-Line HAART | Preferred in many regimens due to its once-daily dosing and “lipid-neutral” profile (less likely to cause high cholesterol). |
| Treatment-Experienced | Used in patients who have developed resistance to other classes of HIV medications. |
| Boosted Regimen | Often co-administered with Ritonavir (100 mg) to “boost” Atazanavir blood levels through CYP3A4 inhibition. |
Mechanism: Protease Enzyme Inhibition
Atazanavir works by sabotaging the final stage of the viral life cycle:
Enzyme Binding: The drug binds to the active site of the HIV-1 Protease enzyme.
Cleavage Blockade: It prevents the enzyme from “cutting” long protein chains (polyproteins) into the smaller, functional proteins the virus needs to assemble.
Immature Virions: The resulting viral particles are structurally defective and cannot infect new CD4 cells.
Viral Load Reduction: This technically leads to a “Log-Drop” in viral load and an increase in CD4 cell counts.
The Pharmacist’s “Technical Warning”
The “Acid Requirement”: Atazanavir absorption is technically dependent on gastric acidity. It must be taken with food.
The “Interaction” Danger: Avoid taking it with Proton Pump Inhibitors (PPIs) like Omeprazole. These drugs raise stomach pH so much that Atazanavir absorption falls below the therapeutic threshold, leading to treatment failure and resistance.
Hyperbilirubinemia: A unique side effect is “Indirect Hyperbilirubinemia” (jaundice). It is technically a benign inhibition of the UGT1A1 enzyme, but it requires patient counseling to prevent alarm.
QT Prolongation: Use with caution in patients taking other medications that prolong the PR or QT interval.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at Healthy Life Pharma / Healthy Inc:
The “Once-Daily” USP: On your digital marketplace, highlight that Atazanavir offers better patient compliance than older PIs that required multiple daily doses. This is a major selling point for B2B government tenders.
Bioequivalence (BE) Data: For international export, especially to African and SE Asian markets, your BE Studies against the innovator (Reyataz) are your strongest asset. Ensure these are highlighted in your technical dossiers.
Stability in Export: Atazanavir Sulfate is sensitive to heat and moisture. Ensure your Alu-Alu or High-Density Polyethylene (HDPE) bottles are validated for “Zone IVb” conditions to maintain the 24-month shelf life required for global NGO procurement.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Atazanavir 300 mg to support your registration in international B2B markets.